Menges, Slovenia

Uros Jamnikar

This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignee: Lek Pharmaceuticals D.d.. Active years: 2021.


% Patents Active = 100.0

 

Average Co-Inventor Count = 2.4

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Uros Jamnikar: Innovator in Recombinant Protein Expression

Introduction

Uros Jamnikar is a notable inventor based in Menges, Slovenia. He has made significant contributions to the field of recombinant protein expression, focusing on methods that enhance productivity and stability in cell line development. With a total of 2 patents, his work is paving the way for advancements in biotechnology.

Latest Patents

Uros Jamnikar's latest patents include innovative methods for predicting genetically stable recombinant protein production in early cell line development. This invention relates to selecting suitable candidate cell clones for recombinant protein expression, utilizing host cells with artificially modified gene expression. His second patent focuses on predicting productivity in early cell line development, again emphasizing the selection of appropriate cell clones and host cells with specific gene modifications.

Career Highlights

Uros Jamnikar is currently employed at Lek Pharmaceuticals D.d., where he applies his expertise in recombinant protein expression. His work is instrumental in advancing the company's research and development efforts in biotechnology.

Collaborations

Uros collaborates with talented coworkers, including Kristina Gruden and Marjanca Blas, contributing to a dynamic research environment that fosters innovation.

Conclusion

Uros Jamnikar's contributions to recombinant protein expression are significant, with his patents reflecting a commitment to advancing biotechnological methods. His work continues to influence the field and drive progress in protein production technologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…